In this issue:
Tirzepatide for HFPEF and obesity
Transcatheter valve repair in HF with moderate–severe mitral regurgitation
Finerenone in HF and chronic kidney disease with type 2 diabetes
Outpatient worsening HF in transthyretin amyloidosis and cardiomyopathy
AF ablation in end-stage HF
1990–2021 trends in HF among patients aged 10–24 years
Cardiac myosin inhibition in HF with normal/supranormal EF
Endovascular ablation of the greater splanchnic nerve in HFPEF
S100A1-derived synthetic peptide improves cardiac performance and survival in HF models
GDMT use during HF hospitalisations in US community health systems
Download PDF